文章摘要
张慧,张蓓蓓,杨冬冬.糖化血红蛋白的变异性对老年终末期糖尿病肾脏病腹膜透析患者预后的影响[J].老年医学与保健,2023,29(6):1165-1169
糖化血红蛋白的变异性对老年终末期糖尿病肾脏病腹膜透析患者预后的影响
Effect of glycosylated hemoglobin variability on the prognosis of elderly patients with end-stage diabetes nephropathy undergo-ing peritoneal dialysis
  
DOI:10.3969/j.issn.1008-8296.2023.06.013
中文关键词: 老年  糖尿病  腹膜透析  糖化血红蛋白  血糖变异
英文关键词: elderly  diabetes  peritoneal dialysis  glycosylated hemoglobin  blood glucose variability
基金项目:
作者单位
张慧 南通市海门区中医院肾脏内科 
张蓓蓓 南通市海门区中医院肾脏内科 
杨冬冬 南通市海门区中医院肾脏内科 
摘要点击次数: 11
全文下载次数: 0
中文摘要:
      目的 探讨糖化血红蛋白(HbA1c)的变异性对老年糖尿病肾脏病腹膜透析患者临床结局的影响.方法 回顾性纳入2013 年6 月—2022 年6 月南通市海门区中医院85 例老年终末期糖尿病肾脏病腹膜透析患者,根据HbA1c变异性将患者分为4 组,HbA1c的变异性被定义为每个患者的变异系数(CV),即HbA1c的标准差与HbA1c的平均值的比例,并采用COX回归进行分析.结果 85 例患者中有44 例死亡(55.3%).多变量分析结果显示,HbA1c变异系数>2.83 是影响患者生存率的主要危险因素(HR为2.88,95%CI 1.21~5.55,P<0.001).Kaplan-Meier分析结果显示,患者生存率随着HbA1c变异系数的增加而降低.结论 HbA1c变异性增加明显升高老年糖尿病肾脏病腹膜透析患者全因死亡率,减少HbA1c变异性可能是改善患者结局的关键策略之一.
英文摘要:
      Objective To investigate the effect of glycosylated hemoglobin(HbA1c)variability on the clinical out-comes of elderly patients with end-stage diabetes nephropathy undergoing peritoneal dialysis.Methods A total of 85 elderly patients with end-stage diabetes nephropathy undergoing peritoneal dialysis in Traditional Chinese Medicine Hospital of Haimen District from June 2013 to June 2022 were retrospectively included.They were divided into 4 groups according to HbA1c varia-bility.The HbA1c variability was defined as the coefficient of variation(CV)for each patient,which was the ratio of the standard deviation of HbA1c to the mean of HbA1c.COX regression was used for analysis.Results Out of 85 patients,44 died(55.3%).The results of multivariate analysis showed that HbA1c CV>2.83 was a significant risk factor affecting patient survival(HR =2.88,95%CI 1.21-5.55,P<0.001).The Kaplan Meier analysis results showed that the survival rate of pa-tients decreased with the increase of HbA1c CV.Conclusion Elevated HbA1c variability significantly increases the all-cause mortality in elderly patients with diabetes nephropathy undergoing peritoneal dialysis.Reducing HbA1c variability may be a key strategy to improve patient outcomes.
查看全文   查看/发表评论  下载PDF阅读器
关闭